esmo 2020 highlights on 1st line durvalumab and tremelimumab for mpdac: the pa.7 study
Published 4 years ago • 1.6K plays • Length 2:35Download video MP4
Download video MP3
Similar videos
-
5:07
esmo 2020 expert video report on 1st line ici for gastro oesophageal cancer
-
2:57
esmo 2020 highlights on lenvatinib plus pembrolizumab in advanced solid tumours: leap-005
-
10:09
esmo 2020 expert video report on long term ici outcomes in lung cancer
-
2:30
#esmo22 highlights on first-line atezolizumab in nsclc not eligible for platinum: the ipsos study
-
35:16
highlights from esmo 2020
-
1:02:24
esmo 2020 lung cancer highlights
-
3:18
#esmo21 highlights on combination of pembrolizumab plus chemotherapy in mtnbc: the keynote-355 study
-
2:11
highlights on 1l nivolumab chemo for metastatic urothelial carcinoma: the checkmate 901 study
-
1:46
esmo oncologypro - intro by dr. e. smyth
-
0:35
preview: priority review in multiple myeloma and 2016 esmo congress highlights
-
2:37
#esmo22 highlights on abemaciclib nsai in hr /her2- advanced breast cancer: the monarch 3 study
-
6:24
highlights of the esmo 2017 lung cancer program | lecia sequist
-
0:58
introducing the esmo magnitude of clinical benefit scale
-
3:49
esmo highlights: genitourinary cancers
-
9:39
esmo 2016: press brief on the monaleesa-2 clinical trial on breast cancer
-
1:06
esmo 2021 highlights in colorectal cancer
-
3:16
phase 1b trial of durvalumab plus tremelimumab for advanced non-small cell lung cancer
-
1:27
durigast: 2l folfiri plus durvalumab plus tremelimumab in gc or ge junction adenocarcinoma
-
1:38
dr. reinmuth on findings from the mystic study